ONXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Onyx Pharmaceuticals, Inc.'s revenue for the three months ended in Jun. 2013 was $153.0 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2013 was $515.9 Mil. Onyx Pharmaceuticals, Inc.'s revenue per share for the three months ended in Jun. 2013 was $2.10. Its revenue per share for the trailing twelve months (TTM) ended in Jun. 2013 was $7.35 Mil.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Onyx Pharmaceuticals, Inc. Revenue for the trailing twelve months (TTM) ended in Jun. 2013 was 89.511 (Sep. 2012 ) + 127.919 (Dec. 2012 ) + 145.492 (Mar. 2013 ) + 153.026 (Jun. 2013 ) = $515.9 Mil.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Onyx Pharmaceuticals, Inc. Annual Data
Onyx Pharmaceuticals, Inc. Quarterly Data